Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD. Just-reported ...

The downside comes after PCVX reports mixed results from a mid-stage study on its pneumococcal vaccine in infants.

The FDA has approved a new pneumococcal vaccine from Merck & Co, just over a month after Pfizer got a green light for a new version of its market leading Prevnar shot. Merck's Vaxneuvance ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

Pfizer PFE is a key player in the PCV vaccine space. PFE markets Prevnar 20, which is approved for the prevention of IPD caused by 20 serotypes in individuals aged six weeks and older. PFE also ...

Last week, Vaxcyte reported top-line results from the mid-stage study that evaluated its 24-valent PCV VAX-24 against Pfizer’s PFE Prevnar 20. The Pfizer vaccine is approved for preventing ...

Capvaxive is a pneumococcal vaccine specifically designed to help protect adults from the serotypes responsible for the majority of invasive pneumococcal disease (IPD) cases. The EC approval of ...